Mersana Therapeutics, Inc. MRSN
29.08 USD 0.00 (+0.00%)
At closeJan 6, 2026, 4:00 PM EST
29.36 +0.28 +0.96%
After hours · Jan 6, 4:00 PM ET
28.78 Day range 29.08
52-week range unavailable
- YTD
- +0.52%
- 1 year
- -14.47%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 6.50 -77.6% downside
Now 29.08
- Target (low)
- 3.00
- Target (mean)
- 6.50
- Target (high)
- 9.00
Ratings (0m) 10 8 buy · 2 hold · 0 sell
- Strong buy0
- Buy8
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.16455 | -0.21 – -0.10627 | -0.158 | -4.2% | 7.64M | -28.6% | 5 |
| Next quarter | -0.17333 | -0.20 – -0.14 | -0.16 | -8.3% | 5.90M | -36.2% | 3 |
| Current year | -0.59413 | -0.65 – -0.54 | -1.40 | +57.6% | 31.77M | -13.8% | 5 |
| Next year | -0.65563 | -0.80 – -0.49836 | -0.59413 | -10.3% | 28.51M | -10.3% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2024 | Citigroup | Maintained | Buy | Buy |
| Aug 14, 2024 | Baird | Maintained | Neutral | Neutral |
| Mar 19, 2024 | JP Morgan | Upgrade | Underweight | Neutral |
| Feb 29, 2024 | Wedbush | Upgrade | Neutral | Outperform |
| Feb 29, 2024 | Truist Securities | Upgrade | Hold | Buy |
| Feb 29, 2024 | Baird | Maintained | Neutral | Neutral |
| Feb 29, 2024 | Guggenheim | Upgrade | Neutral | Buy |
| Dec 4, 2023 | Citigroup | Upgrade | Neutral | Buy |
| Jul 28, 2023 | Citigroup | Downgrade | Buy | Neutral |
| Jul 28, 2023 | Baird | Downgrade | Outperform | Neutral |
| Jul 27, 2023 | Wedbush | Downgrade | Outperform | Neutral |
| Jul 27, 2023 | Truist Securities | Downgrade | Buy | Hold |
| Jun 16, 2023 | Citigroup | Maintained | Buy | Buy |
| Jun 16, 2023 | JP Morgan | Downgrade | Overweight | Neutral |
| Jun 15, 2023 | Guggenheim | Initiated | — | Buy |
| May 11, 2023 | Citigroup | Maintained | — | Buy |
| Mar 16, 2023 | JP Morgan | Upgrade | Neutral | Overweight |
| Nov 21, 2022 | Truist Securities | Initiated | — | Buy |
| Aug 9, 2022 | Baird | Maintained | — | Outperform |
| Aug 9, 2022 | SVB Leerink | Maintained | — | Outperform |
| May 9, 2022 | SVB Leerink | Maintained | — | Outperform |
| Feb 18, 2022 | SVB Leerink | Maintained | — | Outperform |
| Aug 30, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Mar 31, 2021 | Credit Suisse | Initiated | — | Neutral |
| Dec 3, 2020 | Stifel | Initiated | — | Buy |
| Nov 9, 2020 | SVB Leerink | Maintained | — | Outperform |
| May 28, 2020 | Baird | Maintained | — | Outperform |
| May 27, 2020 | SVB Leerink | Reiterated | — | Outperform |
| May 27, 2020 | HC Wainwright & Co. | Reiterated | — | Buy |
| Apr 29, 2020 | BTIG | Initiated | — | Buy |